Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Charles River Associates (CRA) to Present Findings from Recent Work on Patient Tracking and Drug Pricing in Rare Diseases During World Orphan Drug Congress Europe 2019

November 11, 2019 GMT

BOSTON--(BUSINESS WIRE)--Nov 11, 2019--

Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that the Company will review results of recent work on patient tracking and drug pricing in rare diseases in two oral presentations at the World Orphan Drug Congress (WODC) Europe 2019 annual meeting taking place November 12-14 in Barcelona.

Greg Bell, CRA’s Group Vice President and Life Sciences Practice Leader, will present a new tool to track patients with rare diseases who are eligible for available treatments. In addition, Cécile Matthews, Life Sciences Principal at CRA, will review results of an analysis of the factors that payers now consider when making pricing decisions for rare and ultra-rare disease therapies that reach the commercial level, including assessments of disease prevalence, clinical data and levels of unmet medical need.

“As more drug manufacturers focus on research and clinical development of therapies targeting rare diseases, the ability to identify and track patients and the factors payers consider in making pricing and access decisions are critical factors in success,” said Greg Bell. “The Life Sciences Practice team at CRA has completed important studies of these issues and these presentations will outline a range of new approaches and emerging trends that companies must understand and address.”

Presentations by leaders from the CRA Life Sciences Practice on Wednesday, November 13, 2019 during WODC Europe include:

Title: Simplifying patient tracking
Presenter: Greg Bell, Group Vice President and Life Sciences Practice Leader
Session Type: Precision Medicine
Time: 4:45 pm CET

Title: What is the relationship between price and prevalence in non-oncology rare disease?
Presenter: Cécile Matthews, Principal
Session Type: Access & Pricing
Time: 5:10 pm CET

For more information, visit www.crai.com/wodc.

About CRA’s Life Sciences Practice
The CRA Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005328/en/

CONTACT: Media Relations

Charles River Associates



Jamie Bernard, IRC

Senior Associate

Sharon Merrill Associates, Inc.




SOURCE: Charles River Associates

Copyright Business Wire 2019.

PUB: 11/11/2019 08:30 AM/DISC: 11/11/2019 08:30 AM